Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are all blood-borne pathogens and thus share routes of transmission, such as sexual contact, from mother to child during pregnancy (vertical), intravenous drug use (IDU), or blood transfusion \[[@CIT0001]\]. Consequently, a small but significant population of coinfected patients with HIV and chronic viral hepatitis exists \[[@CIT0004], [@CIT0005]\]. It has long been known that patients with HBV or HCV and HIV coinfection have a more rapidly progressing course of liver disease \[[@CIT0006]\] and increased risk of chronic kidney disease \[[@CIT0013]\]. In addition, early initiation of highly active antiretroviral therapy (HAART) is essential to avoid serious acquired immune deficiency syndrome (AIDS)-related events among HIV-infected individuals \[[@CIT0014]\]. As a result, early identification of patients with HIV coinfection among patients with viral hepatitis is crucial. In line with international guidelines, the Danish clinical practice guidelines recommend that all patients newly diagnosed with chronic hepatitis B (CHB) and/or chronic hepatitis C (CHC) are tested for HIV \[[@CIT0002], [@CIT0015], [@CIT0016]\]. Since the Danish clinical practice CHB and CHC guidelines were introduced, a great effort has been made to increase HIV testing of chronic viral hepatitis patients \[[@CIT0015], [@CIT0017]\].

Denmark is a low-prevalence country with regards to HIV, CHB, and CHC with estimated prevalences of approximately 0.2% \[[@CIT0018]\], 0.2% \[[@CIT0019]\], and 0.4% \[[@CIT0020]\], respectively. A previously published Danish regional study suggested an HIV coinfection prevalence of 5% among patients with CHC \[[@CIT0021]\]. However, no peer-reviewed, nationwide studies on Danish patients have been published with regards to the HIV prevalence among chronic viral hepatitis patients.

Previous studies have primarily focused on viral hepatitis coinfection among patients infected with HIV, and nationwide information is lacking on the HIV coinfection prevalence among patients with chronic viral hepatitis and risk factors associated with HIV coinfection.

Therefore, in this nationwide cohort study, we aimed to estimate the prevalence of HIV coinfection among patients newly diagnosed with CHB and CHC in Denmark and to describe changes in the HIV testing prevalence and prevalence of HIV coinfection over time. Moreover, we wished to investigate whether any baseline characteristics of patients newly diagnosed with CHB and/or CHC were associated with HIV coinfection.

MATERIALS AND METHOD {#s5}
====================

Setting {#s6}
-------

All citizens in Denmark are provided with a unique, 10-digit person identification number that permits linkage between multiple data sources. Healthcare services are publicly funded and free of charge to the individual in Denmark. The prospectively collected data used in this nationwide cohort study were extracted from The Danish Database for Hepatitis B and C (DANHEP). The DANHEP is a nationwide database, initiated on January 1, 2002, with ongoing enrollment of all patients over the age of 15 years attending specialized care for CHB and/or CHC in Denmark. Currently, all 18 hospital departments of either infectious diseases, internal medicine with infectious diseases specialists, or gastroenterology are responsible for care of patients with CHB and CHC contribute to DANHEP. The database contains data on patient demographics and clinical and laboratory results.

Study Population {#s7}
----------------

Data from DANHEP were extracted in July 2015. Chronic hepatitis B was defined as a positive hepatitis B surface antigen (HBsAg) before or at least 6 months after enrollment in DANHEP. Chronic hepatitis C was defined as the detection of HCV-ribonucleic acid (RNA) before or within 6 months after enrollment in DANHEP. Chronic infection with HBV and HCV (CHB-CHC) was defined as fulfilling the criteria for both CHB and CHC. All patients enrolled in DANHEP after January 1, 2002 who met the criteria for CHB and/or CHC and who were at least 15 years of age were included in this study. At the date of enrollment in DANHEP, the patient was considered newly diagnosed with chronic viral hepatitis.

We extracted results of HIV antibody/antigen tests performed before or within 6 months of enrollment in DANHEP with viral hepatitis (HIV positive, HIV negative, or unknown HIV status \[[Supplementary Material](#sup3){ref-type="supplementary-material"}\]). An HIV test performed at any point before July 2015, regardless of its relation to enrollment in DANHEP, was defined as "ever HIV tested".

In the presence of conflicting results with regards to HCV-RNA, HBsAg, and HIV antigen/antibody test results registered in DANHEP at enrollment, an ad hoc assessment in each case was performed to determine the hepatitis and HIV status. All laboratory analyses were performed locally at the hospital responsible for care of the patient.

Definition of Covariates {#s8}
------------------------

We categorized the following patient characteristic covariates at enrollment:

1.  • Country of birth (Western Europe \[including Greenland\], Eastern Europe, Africa, Asia, North America, South America, and other)

2.  • Alcohol abuse was defined as the self-reported weekly consumption of more than 14 units of alcohol for women and 21 units of alcohol for men.

3.  • Route of transmission was defined as self-reported suspected route of viral hepatitis transmission (IDU, tattoo/piercing, vertical transmission, sexual transmission, blood/blood product exposure \[including needle injury\], multiple, and other reasons).

4.  • Reason for testing for viral hepatitis (clinical symptoms \[including elevated liver function tests\]; screening during pregnancy; screening for other reasons \[including screening of persons with known risk factors defined by the Danish Health and Medicines Authorities {[Supplementary Material](#sup3){ref-type="supplementary-material"}}\] \[[@CIT0015]\]; and other reasons)

5.  • Sex (male, female)

6.  • Age at enrollment

7.  • Clinical cirrhosis (yes/no) was defined as the presence of clinical signs of cirrhosis before or up to 6 months after the enrollment date (oesophageal varices, ascites, and hepatic encephalopathy).

8.  • HCV genotype

Statistical Analyses {#s9}
--------------------

Baseline characteristics are presented as median with interquartile range or absolute and relative frequencies. Differences in patient characteristics between hepatitis groups (CHB, CHC, and CHB-CHC) were tested for statistical significance by applying the Kruskal-Wallis, Fisher's exact test, χ^2^, or χ^2^ test with Montecarlo simulation using 10000 samples, whenever appropriate. The prevalence of HIV coinfection with 95% confidence interval (CI) was calculated using the Clopper-Pearson \[[@CIT0022]\] exact method as the number of HIV-positive individuals divided by the total number of patients including patients with unknown HIV status. To estimate the risk of HIV coinfection (HIV positive vs HIV nonpositive) associated with different hepatitis groups, univariate logistic regression was applied. To estimate the change in HIV coinfection prevalence over time between 2002 and 2015, we used multiple logistic regression analysis with year of enrollment in DANHEP as a continuous covariate and adjusted for sex, age, and country of birth. Year of enrollment and age were tested for log linearity, and because age did not show log linearity it was introduced as a categorical covariate. To estimate the risk of HIV coinfection associated with sex, age, and country of birth (Western Europe as reference), we used univariate logistic regression models. The risk of HIV coinfection associated with route of transmission was estimated using multiple logistic regression models adjusting for confounding factors. Further details on the handling of the substantial number of missing values for route of transmission can be found in the [Supplementary Material](#sup3){ref-type="supplementary-material"}. All logistic regression models were determined on the basis of directed acyclic graphs \[[@CIT0023]\] to reduce bias ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Human immunodeficiency virus testing and HIV coinfection prevalence were compared between departments of gastroenterology and hepatology versus departments with infectious diseases specialists using the χ^2^ test.

Multiple logistic regression models were tested for goodness-of-fit by applying the Hosmer-Lemeshow test \[[@CIT0024]\]. Statistical tests were 2-sided, and *P* \< .05 was considered statistically significant. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC), and figures were created using R studio \[[@CIT0025]\].

Ethical Approval {#s10}
----------------

This study was approved by the Danish Data Protection agency in accordance with Danish law (J.nr. 2012-58-0023).

RESULTS {#s11}
=======

Study Population {#s12}
----------------

As of July 2015, 10784 patients had been enrolled in DANHEP. We excluded 2294 patients in total, 1715 of whom patients were enrolled before January 1, 2002, 517 patients did not fulfill the definitions of either CHB or CHC, and 62 patients were \<15 years. Of the 8490 patients included, 3091 had CHB, 5305 had CHC, and 94 had both CHB and CHC. Baseline characteristics stratified by hepatitis group are presented in [Table 1](#T1){ref-type="table"}. Patients with CHB were younger than CHC and CHB-CHC patients, and the distribution of sex differed between the hepatitis groups with more female CHB patients than CHC and CHB-CHC patients. The overall prevalence of HIV was 4.4% (95% CI, 4.0--4.9), and the prevalence was 2.9% (95% CI, 2.3--3.5) among CHB patients, 5.3% (95% CI, 4.7--5.9) among CHC patients, and 6.4% (95% CI, 2.4--13.4) among CHB-CHC patients (*P* \< .0001).

###### 

Baseline Characteristics

  ---------------------------------------------------------------------------------------------------------------------------------
  Variable                            Chronic Hepatitis B   Chronic Hepatitis C   Chronic Hepatitis B and C   Total^a^
  ----------------------------------- --------------------- --------------------- --------------------------- ---------------------
  Number (%)                          3091 (36.4)           5305 (62.5)           94 (1.1)                    8490

  Age at diagnosis (median, q1, q3)   34.9 (27.6--44.8)     45.0 (36.6--52.4)     41.3 (35.0--49.2)           41.4 (32.4--50.5),\
                                                                                                              *P* \< .0001

  Women, N (%)                        1654 (53.5)           1768 (33.3)           27 (28.7)                   3449 (40.6)

                                                                                                              *P* \< .0001

  HIV status                                                                                                  

  Positive                            89 (2.9)              281 (5.3)             6 (6.4)                     376 (4.4)

  Negative                            2198 (71.1)           4119 (77.6)           67 (71.3)                   6384 (75.2)

  Unknown                             804 (26.0)            905 (17.1)            21 (22.3)                   1730 (20.4)

                                                                                                              *P* \< .0001^b^

  Origin/country of birth             450 (14.6)            129 (2.4)             4 (4.3)                     583 (6.9)

  Africa                              1592 (51.5)           409 (7.7)             20 (21.3)                   2021 (23.8)

  Asia                                285 (9.2)             262 (4.9)             4 (4.3)                     551 (6.5)

  Eastern Europe                      2 (0.1)               21 (0.4)              \-                          23 (0.3)

  North America                       13 (0.4)              32 (0.6)              \-                          45 (0.5)

  South America                       509 (16.5)            4279 (80.7)           61 (64.9)                   4849 (57.1)

  Western Europe^c^                   47 (1.5)              16 (0.3)              \-                          63 (0.7)

  Other^d^                            193 (6.2)             157 (3.0)             5 (5.3)                     355 (4.2)

  Unknown                                                                                                     *P* \< .0001

  Route of transmission               61 (2.0)              268 (5.1)             \-                          329 (3.9)

  Blood/blood product exposure^e^     67 (2.2)              3238 (61.0)           53 (56.4)                   3358 (39.6)

  IDU                                 126 (4.1)             164 (3.1)             1 (1.1)                     291 (3.4)

  Sexual contact                      14 (0.5)              107 (2.0)             2 (2.1)                     123 (1.5)

  Tattoo/piercing                     886 (28.7)            25 (0.5)              7 (7.5)                     918 (10.8)

  Vertical                            \-                    13 (0.3)              \-                          13 (0.2)

  Multiple                            74 (2.4)              70 (1.3)              4 (4.3)                     148 (1.7)

  Other reason                        1863 (60.3)           1420 (26.8)           27 (28.7)                   3310 (39.0)

  Unknown                                                                                                     *P* \< .0001

  Diagnostic test reason              544 (17.6)            1585 (29.9)           28 (29.8)                   2157 (25.4)

  Clinical symptoms                   372 (12.0)            590 (11.1)            13 (13.8)                   975 (11.5)

  Other reason                        450 (14.6)            52 (1.0)              1 (1.1)                     503 (5.9)

  Screening pregnancy                 1063 (34.4)           1624 (30.6)           20 (21.3)                   2707 (31.9)

  Screening other                     662 (21.4)            1454 (27.4)           32 (34.0)                   2148 (25.3)

  Unknown                                                                                                     *P* \< .0001

  History of alcohol abuse            128 (4.1)             1348 (25.4)           17 (18.1)                   1493 (17.6)\
                                                                                                              *P* \< .0001

  HCV genotype                                                                                                

  Genotype 1                          \-                    2086 (39.3)           33 (35.1)                   2119 (39.3)

  Genotype 2                          \-                    388 (7.3)             4 (4.3)                     392 (7.3)

  Genotype 3                          \-                    2049 (38.6)           25 (26.6)                   2074 (38.4)

  Genotype 4--6                       \-                    140 (2.6)             2 (2.1)                     142 (2.6)

  Multiple genotypes                  \-                    54 (1.0)              2 (2.1)                     56 (1.0)

  Unknown                             \-                    588 (11.1)            28 (29.8)                   616 (11.4)

                                                                                                              *P* = .49

  Clinical cirrhosis                  31 (1.0)              219 (4.1)             2 (2.1)                     252 (3.0)

                                                                                                              *P* \< .0001
  ---------------------------------------------------------------------------------------------------------------------------------

Abbreviations: HIV, human immunodeficiency virus; IDU, intravenous drug use.

^a^Kruskal-Wallis, Fisher's exact, χ^2^ test, or χ^2^ test with Montecarlo simulation using 10000 samples when appropriate.

^b^HIV positive vs not HIV positive.

^c^Including Greenland.

^d^Including Australia, New Zealand, and Pacific Islands.

^e^Including needle stick injuries.

Human Immunodeficiency Virus-Coinfected Patients {#s13}
------------------------------------------------

Baseline characteristics of patients with HIV coinfection can be seen in [Table 2](#T2){ref-type="table"} and [Supplementary Table 1](#sup3){ref-type="supplementary-material"}. The majority of HIV-coinfected patients had CHC (75%), and their demographic characteristics were akin to that of the CHC population with regards to the distribution of sex and country of birth. Sexual route of viral hepatitis transmission was more prevalent among HIV-positive patients (22.1% vs 2.7%), and vertical transmission of viral hepatitis was rare in HIV-coinfected patients (0.8% vs 9.8%).

###### 

Patient Characteristics of HIV-Positive Patients, HIV-Negative Patients, and Patients With Unknown HIV Status

  Patient Characteristic            HIV Positive        HIV Negative        HIV Unknown         *P* Value^a^
  --------------------------------- ------------------- ------------------- ------------------- --------------
  Number                            376                 6384                1730                
  Age, median (IQR)                 40.3 (34.7--47.7)   41.4 (32.5--50.5)   41.9 (31.4--51.3)   .8
  Women, N (%)                      91 (24.2)           2550 (40.0)         808 (46.7)          \<.0001
  Hepatitis type                                                                                
  Hepatitis B                       89 (23.7)           2198 (34.4)         804 (46.5)          \<.0001
  Hepatitis C                       281 (74.7)          4119 (64.5)         905 (52.3)          
  Hepatitis B and C                 6 (1.6)             67 (1.1)            21 (1.2)            
  Country of Birth, N (%)                                                                       
  Africa                            30 (8.0)            431 (6.8)           122 (7.1)           \<.0001
  Asia                              37 (9.8)            1484 (23.3)         500 (28.9)          
  Eastern Europe                    19 (5.1)            437 (6.9)           95 (5.5)            
  North America                     1 (0.3)             15 (0.2)            7 (0.4)             
  South America                     8 (2.1)             32 (0.5)            5 (0.3)             
  Western Europe^b^                 273 (72.6)          3728 (58.4)         848 (49.0)          
  Other^c^                          3 (0.8)             39 (0.6)            21 (1.2)            
  Unknown                           5 (1.3)             218 (3.4)           132 (7.6)           
  Route of Transmission, N (%)                                                                  
  Blood/blood product exposure^d^   11 (2.9)            235 (3.7)           83 (4.8)            \<.0001
  IDU                               166 (44.2)          2708 (42.4)         484 (28.0)          
  Sexual contact                    83 (22.1)           172 (2.7)           36 (2.1)            
  Tattoo/piercing                   2 (0.5)             96 (1.5)            25 (1.5)            
  Vertical                          3 (0.8)             625 (9.8)           290 (16.8)          
  Multiple                          0 (-)               11 (0.2)            2 (0.1)             
  Other Reason                      2 (0.5)             112 (1.8)           34 (2.0)            
  Unknown                           109 (29.0)          2425 (38.0)         776 (44.9)          
  Diagnostic Test Reason, N (%)                                                                 
  Clinical symptoms                 77 (20.5)           1565 (24.5)         515 (29.8)          \<.0001
  Other reason                      34 (9.0)            773 (12.1)          168 (9.7)           
  Screening pregnancy               2 (0.5)             402 (6.3)           99 (5.7)            
  Screening other                   137 (36.4)          2025 (31.7)         545 (31.5)          
  Unknown                           126 (33.5)          1619 (25.4)         403 (23.3)          
  History of alcohol abuse, N (%)   45 (12.0)           1205 (18.9)         243 (14.1)          \<.0001
  HCV Genotype, N (%)^e^                                                                        
  Genotype 1                        133 (46.3)          1626 (38.8)         360 (38.9)          \<.0001
  Genotype 2                        17 (5.9)            290 (6.9)           85 (9.2)            
  Genotype 3                        81 (28.2)           1670 (39.9)         323 (34.9)          
  Genotype 4--6                     22 (7.7)            89 (2.1)            31 (3.4)            
  Multiple genotypes                5 (1.7)             41 (1.0)            10 (1.1)            
  Unknown                           29 (10.1)           470 (11.2)          117 (12.6)          
  Clinical cirrhosis, N (%)         5 (1.3)             196 (3.1)           51 (3.0)            .15

Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, intravenous drug use; IQR, interquartile range.

^a^Kruskal-Wallis, χ^2^ test, or χ^2^ test with Montecarlo simulation using 10000 samples when appropriate.

^b^Including Greenland.

^c^Including Australia, New Zealand, and Pacific Islands.

^d^Including needle stick injuries.

^e^Genotype distribution among patients with chronic hepatitis C.

Human Immunodeficiency Virus Testing {#s14}
------------------------------------

In the entire study population, 79.6% were tested for HIV as newly diagnosed with viral hepatitis at enrollment in DANEHP and 87.8% of patients were ever tested for HIV coinfection before July 2015. In addition to HIV-positive patients identified at enrollment in DANHEP, an additional 20 patients were diagnosed with HIV coinfection a median of 44 months (range, 9--116) after enrollment. Seven of these 20 patients were not HIV tested at enrollment and had their first positive HIV test performed a median of 41 months after enrollment (range, 9--116). The remaining 13 patients were HIV negative at enrollment in DANHEP and subsequently became HIV positive after a median of 47 months (range, 11--101).

The HIV testing prevalence among newly diagnosed chronic viral hepatitis patients increased from 64.5% in 2002 to 87.7% in 2014, respectively, whereas the prevalence of HIV coinfection among newly enrolled patients during the same period fell from 7.8% (95% CI, 5.5--10.7) in 2002 to 1.6% (95% CI, 0.7--3.2) in 2014. Human immunodeficiency virus coinfection status (positive, negative, unknown) for all patients, CHB and CHC patients, in relative and absolute frequencies, for each year of enrollment between 2002 and 2014 (the last year with complete data), are shown in [Figure 1A--C](#F1){ref-type="fig"} and [Supplementary Figure 2A--C](#sup2){ref-type="supplementary-material"}, respectively. Departments of gastroenterology and hepatology were less likely to test for HIV than departments with infectious disease specialists (70.4% vs 82.8%, *P* \< .0001) ([Supplementary Table 2](#sup3){ref-type="supplementary-material"}).

![Human immunodeficiency virus (HIV)-status in percentage among all newly diagnosed patients with chronic viral hepatitis between 2002 and 2014. (A) All patients. (B) Patients with chronic hepatitis B virus (HBV) infection. (C) Patients with chronic hepatitis C virus (HCV) infection.](ofy31001){#F1}

Patient Characteristics Associated With Human Immunodeficiency Virus Coinfection {#s15}
--------------------------------------------------------------------------------

We found that CHC was associated with HIV coinfection with an odds ratio (OR) of 1.89 (95% CI, 1.48--2.41) compared with CHB patients. After adjusting for sex, age and country of birth, we found that the prevalence of HIV coinfection decreased over time between 2002 and 2015 with an OR of HIV coinfection of 0.84 (95% CI, 0.82--0.87) per year. Estimates of OR for HIV coinfection associated with baseline characteristics are listed in [Table 3](#T3){ref-type="table"}. We found that age 35--50 years (OR = 4.42; 95% CI, 1.40--13.94), male sex (OR = 2.21; 95% CI, 1.74--2.81), birth in South America (OR = 3.62; 95% CI, 1.67--7.86), and sexual transmission of viral hepatitis (OR = 8.81; 95% CI, 6.30--12.33) were associated with HIV coinfection. We were surpised to find that all 8 HIV-coinfected patients from South America had CHC, 7 of whom reported sexual route of viral hepatitis transmission. Birth in Asia (OR = 0.31; 95% CI, 0.22--0.44) and vertical transmission of viral hepatitis (OR = 0.09; 95% CI, 0.03--0.29) were negatively associated with HIV coinfection.

###### 

Risk Factors Associated With HIV Coinfection Among Patients With Newly Diagnosed Chronic Viral Hepatitis B and/or C

  Risk Factor                                              Odds Ratio (95% CI)    N
  -------------------------------------------------------- ---------------------- ------
  Patients with CHC vs CHB^a^                              1.89 (1.48--2.41)      8490
  Patients with CHB-CHC vs CHB^a^                          2.3 (0.98--5.40)       8490
  Age^b^, years                                                                   
  ≤35                                                      2.64 (0.83--8.39)      8490
  \>35--≤50                                                4.42 (1.40--13.94)     
  \>50--≤65                                                2.41 (0.75--7.73)      
  \>65                                                     Reference              
  Sex, men vs women^c^                                     2.21 \[1.74; 2.81\]    8490
  Year of enrollment^d^                                    0.84 \[0.82; 0.87\]    8135
  Country of birth, Africa vs WE^e^                        0.91 \[0.62; 1.34\]    8135
  Country of birth, Asia vs WE^e^                          0.31 \[0.22; 0.44\]    8135
  Country of birth, Eastern Europe vs WE^e^                0.60 \[0.37; 0.96\]    8135
  Country of birth, North America vs WE^e^                 0.76 \[0.10; 5.67\]    8135
  Country of birth, South America vs WE^e^                 3.62 \[1.67; 7.86\]    8135
  Route of transmission, blood exposure vs IDU^f^          0.67 \[0.34; 1.29\]    5023
  Route of transmission, sexual transmission vs IDU^f^     8.81 \[6.30; 12.33\]   5023
  Route of transmission, tattoo/piercing vs IDU^f^         0.30 \[0.07; 1.26\]    5023
  Route of transmission, vertical transmission vs IDU^f^   0.09 \[0.03; 0.29\]    5023

Abbreviations: CHB, chronic hepatitis B virus; CHC, chronic hepatitis C virus; CI, confidence interval; IDU, intravenous drug use; OR, odds ratio; WE, Western Europe.

^a^Univariate, type 3 test (*P* \< .0001).

^b^Univariate, type 3 test (*P* \< .0001).

^c^Univariate.

^d^Adjusted for sex, age, and country of birth.

^e^Univariate, type 3 test (*P* \< .0001).

^f^Adjusted for age, sex, year of enrollment, country of birth, type 3 (*P* \< .0001).

DISCUSSION {#s16}
==========

In this nationwide cohort study of patients with newly diagnosed chronic viral hepatitis attending specialized care, we found an overall prevalence of HIV coinfection of 4.4% and an increase in HIV testing prevalence coinciding with a decrease in the prevalence of HIV coinfection since 2002. Chronic hepatitis C or CHB-CHC, younger age, male sex, birth in South America, and sexual transmission of viral hepatitis were associated with a higher prevalence of HIV coinfection. In contrast, patients of Asian origin and patients vertically infected with viral hepatitis showed a lower prevalence HIV coinfection.

The prevalence of HIV coinfection among CHB patients found in our study is slightly lower than the estimates published from other low HIV-prevalence settings (United States) of 5.2%--6.3% among CHB patients \[[@CIT0026], [@CIT0027]\], whereas the overall HIV coinfection prevalence of 5.3% among CHC patients found in our study was similar to estimates found in larger CHC patient cohorts from the United Kingdom (UK) and the United States at 5.0% and 4.3%, respectively \[[@CIT0027], [@CIT0028]\].

Demographics of CHB patients in our study differed from CHB patients in the US-based studies \[[@CIT0026], [@CIT0027]\] with fewer from Asia, fewer women, and more were sexually infected with HIV, whereas the demographic characteristics of CHC patients in our study were similar to patients with CHC included in the UK study \[[@CIT0028]\]. However, no previous nationwide study has been conducted, and a systematic review found considerable variation in the prevalence of HIV coinfection among European patients with CHC living with intravenous drug use, ranging from 0% to 70% \[[@CIT0029]\]. The low HIV prevalence in the Danish population \[[@CIT0018]\], the nationwide design with inclusion of viral hepatitis patients from various risk groups, may partly explain differences between the HIV coinfection prevalence found in the Danish viral hepatitis population and those described elsewhere \[[@CIT0026], [@CIT0030], [@CIT0031]\]. Moreover, the universal access to healthcare services and drug addiction treatment with needle exchange programs (all free of charge) in Denmark \[[@CIT0032]\] may be partly responsible.

Although we have no data to draw any definitive conclusions as to why the HIV coinfection prevalence is declining in the Danish chronic viral hepatitis population, one could speculate that access to HAART (which reduces sexual HIV transmission \[[@CIT0033]\]), needle exchange programs, and/or oral opioid substitution therapy of intravenous drug users may play a role. Our data showed a steady increase in the proportion of patients tested for HIV throughout the study period, which is most likely the result of a national effort to increase HIV testing in risk groups \[[@CIT0015]\], the process of making HIV testing routine in all patients newly diagnosed with chronic viral hepatitis, and the introduction of screening for HIV in pregnant women. The importance of knowledge about HIV by the physician may be indicated by the fact that patients attending departments of infectious diseases appeared to be more likely to be tested for HIV than patients attending departments of gastroenterology.

Approximately 60% of the Danish CHC cohort is infected with HCV through IDU, and the majority are males and infected in Denmark \[[@CIT0020], [@CIT0034]\]. In contrast, the population of CHB patients in Denmark comprises primarily relatively younger women, many of whom were vertically infected with HBV in their country of origin, often Asia, Africa, and the Middle East \[[@CIT0035]\]. Immigration, and the introduction of nationwide screening of pregnant women for HBV in 2005 and HIV infection in 2010 in Denmark \[[@CIT0036], [@CIT0037]\], may have influenced the demographics of the chronic viral hepatitis cohort and their HIV coinfection prevalence because the prevalence of HIV infection is very low among pregnant women in Denmark (0.06% HIV infected among all pregnant women tested in 2016 \[[@CIT0038]\]). Only 1 of 203 (0.5%) HBsAg-positive pregnant women were also HIV positive (M. Wessman, written personal communication, 15 December 2017). The majority of individuals infected with HIV in Denmark are male, with a median age of 34 years at HIV diagnosis, approximately half of whom have been infected through homosexual transmission, and only approximately 10% are infected through IDU \[[@CIT0039], [@CIT0040]\]. Hence, it was not surprising to find that younger age, male sex, and sexual transmission of viral hepatitis were associated with a higher prevalence of HIV coinfection and that Asian origin and vertical transmission were associated with a lower HIV coinfection prevalence. The higher risk of HIV coinfection associated with HCV seen in this study is presumed to be due to underlying differences in behavioral risks (eg, IDU, men who have sex with men \[MSM\] \[[@CIT0041]\]) and not due to a causal link between HCV and HIV per se. However, our data limit further conclusions on whether sexual transmission was in fact more likely to be among MSM or sex workers. A more surprising finding was the association between South American origin and HIV coinfection. Our study included very few patients from South America with a surprisingly high HIV coinfection prevalence among CHC patients---approximately all of whom had been sexually infected with HCV. The HIV epidemic in South and Central America varies, but in many countries it is driven by transmission among MSM \[[@CIT0042]\], with a median HCV seroprevalence of 11% among people living with HIV/AIDS, with considerable variation throughout the region \[[@CIT0043]\]. Thus, the association could represent a selected group of South American patients with high-risk behavior but is most likely the result of a spurious finding.

A major strength of our study is the nationwide design with comprehensive data. However, the fact that Denmark is a low-prevalence country with regards to HBV, HCV, and HIV limits the generalizability to other settings. Despite the nationwide design, DANHEP only includes patients with CHB or CHC attending specialized care. There are a substantial number of patients in Denmark with either undiagnosed chronic viral hepatitis or diagnosed viral hepatitis but not enrolled in specialized care \[[@CIT0019], [@CIT0020]\]. In addition, DANHEP does not include detailed information on homosexual and heterosexual behavior or sex work, and a large proportion of patients had unknown route of transmission. Whether this is due to genuine ignorance about the route of transmission or an unwillingness to reveal behavioral risks (such as MSM, sex work, or IDU) is unknown.

Because HIV, HBV, and HCV are blood-borne viruses and share routes of transmission, patients diagnosed with viral hepatitis have at least 1 risk factor for HIV coinfection (ie, IDU, vertical transmission etc). An HIV test is cheap, easy to perform, and associated with negligible health risks, and because the consequences of missing an HIV diagnosis can have detrimental consequences, we strongly recommend HIV testing all viral hepatitis patients regardless of their risk profile. Our results also indicate that there is still room for improvement in HIV testing among chronic viral hepatitis patients in Denmark, but a continuous focus on this area may well lead to improvements in HIV testing frequencies.

CONCLUSIONS {#s17}
===========

In conclusion, in this nationwide study including patients with newly diagnosed chronic viral hepatitis, the prevalence of HIV coinfection in Denmark decreased between 2002 and 2014 concurrently with an observed increase in HIV testing prevalence. The overall prevalence of HIV coinfection was approximately 4%, but it was higher among patients with CHC and CHB-CHC coinfection than patients with CHB and higher among patients of male sex, younger age, and with sexual transmission of viral hepatitis.
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